REGULATORY
Daiichi Sankyo’s Nasal Flu Vaccine Up for MHLW Panel Review on February 27
Japan’s key health ministry advisory panel will discuss whether to put forward a package of medicines for approval at its upcoming meeting on February 27, including Daiichi Sankyo’s nasal spray (live attenuated) flu vaccine. If given the thumbs-up, it would…
To read the full story
Related Article
- Pfizer’s Omicron-Tailored Jab for Ages 5-11 on PAFSC Agenda for Feb. 27
February 16, 2023
REGULATORY
- Japan to Start CEA Technical Discussions as Early as May 25
May 20, 2026
- LDP Study Group’s Honebuto Proposal Urges “Freeze” on On-Patent Drug Price Cuts
May 20, 2026
- PMDA Flags Iron Products, ST Combination Drug in Risk Review
May 20, 2026
- MHLW Orders Detailed Report on Tavneos Efficacy Concerns
May 20, 2026
- Japan Approves Jascayd, mNEXSPIKE, Zepbound OSA Use, Others
May 19, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





